Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT | Zendy

Erin A. Bohula | Zendy; Robert P. Giugliano | Zendy; Christopher P. Can | Zendy; Jing Zhou | Zendy; Sabina A. Murphy | Zendy; Jennifer A. White | Zendy; Andrew M. Tershakovec | Zendy; Michael A. Blazing | Zendy; Eugene Braunwald | Zendy

Open Access

Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT

Author(s) -

Erin A. Bohula,

Robert P. Giugliano,

Christopher P. Can,

Jing Zhou,

Sabina A. Murphy,

Jennifer A. White,

Andrew M. Tershakovec,

Michael A. Blazing,

Eugene Braunwald

Publication year - 2015

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.115.018381

Subject(s) - medicine , ezetimibe , simvastatin , c reactive protein , cholesterol , dual (grammatical number) , statin , endocrinology , cardiology , inflammation , art , literature

Statins lower low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hs-CRP); addition of ezetimibe to statins further reduces LDL-C and hs-CRP. An analysis of the relationship between achieved LDL-C and hs-CRP targets and outcomes for simvastatin and ezetimibe/simvastatin was prespecified in Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research